Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 5, 2005, Pages 529-539

  Chaobal, Harshvardhan N ^a   Kharasch, Evan D ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; CYTOCHROME P450 3A; MIDAZOLAM; RIFAMPICIN; TROLEANDOMYCIN;

ACCURACY; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GRAPEFRUIT JUICE; HUMAN; HUMAN EXPERIMENT; LINEAR REGRESSION ANALYSIS; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; SAMPLING; VOLUNTEER;

EID: 28144449045     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.08.004     Document Type: Article

References (33)

1. J.K. Lamba, Y.S. Lin, E.G. Schuetz, K.E. Thummel Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Deliv Rev 54 2002 1271 1294
2. O. Burk, L. Wojnowski Cytochrome P450 3A and their regulation Naunyn Schmiedebergs Arch Pharmacol 369 2004 105 124
3. H.G. Xie, A.J. Wood, R.B. Kim, C.M. Stein, G.R. Wilkinson Genetic variability in CYP3A5 and its possible consequences Pharmacogenomics 5 2004 243 272
4. R. Harris, G. Jang, S. Tsunoda Dietary effects on drug metabolism and transport Clin Pharmacokinet 42 2003 1071 1088
5. D.S. Streetman, J.S. Bertino Jr, A.N. Nafziger Phenotyping of drug-metabolizing enzymes in adults a review of in-vivo cytochrome P450 phenotyping probes Pharmacogenetics 10 2000 187 216
6. G.T. Tucker, J.B. Houston, S.-M. Huang Optimizing drug development strategies to assess drug metabolism/transporter interaction potential-toward a consensus Clin Pharmacol Ther 70 2001 103 114
7. T.D. Bjornsson, J.T. Callaghan, H.J. Einolf, V. Fischer, L. Gan, S. Grimm The conduct of in vitro and in vivo drug-drug interaction studies a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective Drug Metab Dispos 31 2003 815 832
8. J.F. Rogers, M.L. Rocci Jr, D.B. Haughey, J.S. Bertino Jr An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity Clin Pharmacol Ther 73 2003 153 158
9. J.W. Mandema, B. Tuk, A.L. van Steveninck, D.D. Breimer, A.F. Cohen, M. Danhof Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite a-hydroxymidazolam in healthy volunteers Clin Pharmacol Ther 51 1992 715 728
10. T.M. Klees, P. Sheffels, K.E. Thummel, E.D. Kharasch Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5 Anesthesiology 102 2005 550 556
11. E.D. Kharasch, M. Russell, D. Mautz, K.E. Thummel, K.L. Kunze, T.A. Bowdle The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions Anesthesiology 87 1997 36 50
12. S. Phimmasone, E.D. Kharasch A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans Clin Pharmacol Ther 70 2001 505 517
13. E.D. Kharasch, C. Hoffer, A. Walker, P. Sheffels Disposition and miotic effects of oral alfentanil a potential noninvasive probe for first-pass cytochrome P4503A activity Clin Pharmacol Ther 73 2003 199 208
14. E.D. Kharasch, A. Walker, C. Hoffer, P. Sheffels Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass CYP3A activity. Noninvasive assessment using pupillary miosis Clin Pharmacol Ther 76 2004 452 466
15. M. Chauvin, F. Bonnet, C. Montembault, J.C. Levron, P. Viars The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans measurement of alfentanil hepatic extraction coefficient Anesth Analg 65 1986 999 1003
16. M. Chauvin, C. Lebrault, J.C. Levron, P. Duvaldestin Pharmacokinetics of alfentanil in chronic renal failure Anesth Analg 66 1987 53 56
17. W. Meuldermans, A. Van Peer, J. Hendrickx, R. Woestenborghs, W. Lauwers, J. Heykants Alfentanil pharmacokinetics and metabolism in humans Anesthesiology 69 1988 527 534
18. T.K. Henthorn, T.C. Krejcie, M.J. Avram The relationship between alfentanil distribution kinetics and cardiac output Clin Pharmacol Ther 52 1992 190 196
19. D.Z. D'Argenio Optimal sampling times for pharmacokinetic experiments J Pharmacokinet Biopharm 9 1981 739 756
20. J.J. DiStefano III Optimized blood sampling protocols and sequential design of kinetic experiments Am J Physiol 240 1981 R259 R265
21. B.T. Sørensen, A. Strömgren, P. Jakobsen, A. Jakobsen A limited sampling method for estimation of the carboplatin area under the curve Cancer Chemother Pharmacol 31 1993 324 327
22. G. Suarez-Kurtz, F.L. Vicente, C.G. Ponte, V.L. Buy, C.J. Struchiner Limited-sampling strategy models for estimating the area under the plasma concentration-time curve for amlodipine Eur J Clin Pharmacol 55 1999 651 657
23. G. Suarez-Kurtz, F.M. Ribeiro, F.L. Vicente, C.J. Struchiner Development and validation of limited-sampling strategies for predicting amoxicillin pharmacokinetic and pharmacodynamic parameters Antimicrob Agents Chemother 45 2001 3029 3036
24. Y.S. Lin, G.F. Lockwood, M.A. Graham, W.R. Brian, C.M. Loi, M.R. Dobrinska In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration Pharmacogenetics 11 2001 781 791
25. G. Filler, J. Feber, N. Lepage, G. Weiler, I. Mai Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children Pediatr Transplant 6 2002 411 418
26. A. Di Paolo, R. Danesi, F. Vannozzi, A. Falcone, E. Mini, L. Cionini Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer Clin Pharmacol Ther 72 2002 627 637
27. I. Kramer, K. Dalhoff, J.O. Clemmesen, S. Loft, H.E. Poulsen Comparison of chlorzoxazone one-sample methods to estimate CYP2E1 activity in humans Eur J Clin Pharmacol 59 2003 775 778
28. J.S. Kim, A.N. Nafziger, S.M. Tsunoda, E.E. Choo, D.S. Streetman, A.D. Kashuba Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults application to various assay techniques J Clin Pharmacol 42 2002 376 382
29. N. Akaike A new look at the statistical model identification IEEE Trans Auton Control 19 1974 716 723
30. D.G. Altman, J.M. Bland Measurement in medicine the analysis of method comparison studies Statistician 32 1983 307 317
31. X.L. Meng, R. Rosenthal, D.B. Rubin Comparing correlated correlation coefficients Psych Bull 111 1992 172 175
32. C.L. Zimmerman, J.T. Slattery Maintenance-dose prediction based on a single determination of concentration general applicability to two-compartment drugs with reference to lithium J Pharm Sci 72 1983 1262 1266
33. J.H. Oppenheimer, H.L. Schwartz, M.I. Surks Determination of common parameters of iodothyronine metabolism and distribution in man by noncompartmental analysis J Clin Endocrinol Metab 41 1975 319 324